Skip to main content

Drug Interactions between Doxil and oteseconazole

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

DOXOrubicin liposomal oteseconazole

Applies to: Doxil (doxorubicin liposomal) and oteseconazole

ADJUST DOSE: Coadministration with oteseconazole may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP), which may increase the risk of adverse effects associated with these drugs. The proposed mechanism is decreased clearance due to inhibition of BCRP-mediated intestinal and/or hepatic transport by oteseconazole. When administered with rosuvastatin, a BCRP substrate, oteseconazole increased rosuvastatin peak plasma concentration (Cmax) and systemic exposure (AUC 0-24h) by 118% and 114%, respectively.

MANAGEMENT: When concomitant use of oteseconazole is required, the lowest possible starting dosage or a reduction of the existing dosage of BCRP substrates should be considered. The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a BCRP inhibitor like oteseconazole and for any dosage adjustments that may be required. Patients should be closely monitored for clinical response and adverse effects, and the dosage(s) of concomitant medication(s) further adjusted as necessary.

References

  1. (2022) "Product Information. Vivjoa (oteseconazole)." Mycovia Pharmaceuticals, Inc.

Switch to consumer interaction data

Drug and food interactions

Moderate

oteseconazole food

Applies to: oteseconazole

ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of oteseconazole. When administered with a high-fat, high-calorie meal (800 to 1000 calories; 50% fat), oteseconazole peak plasma concentration (Cmax) and systemic exposure (AUC 0-72h) increased by 45% and 36%, respectively. However, no significant differences were observed with a low-fat, low-calorie meal.

MANAGEMENT: Oteseconazole should be administered with food.

References

  1. (2022) "Product Information. Vivjoa (oteseconazole)." Mycovia Pharmaceuticals, Inc.

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer